Monitoring

Your Organisational Guidance

ebpracticenet urges you to prioritise the following organisational guidance:

Kleincellige en niet-kleincellige longkanker: diagnose, behandeling en opvolgingPublished by: KCELast published: 2013Cancer du poumon à petites cellules et non à petites cellules : diagnostic, traitement et suiviPublished by: KCELast published: 2013

After potentially curative treatment for lung cancer, patients should be followed regularly to assess for disease recurrence and treatment-related toxicity.[302]

Following radiotherapy patients may develop inflammation of the lung, termed pneumonitis.[164]​ This is rarely lethal but may require treatment. Chemotherapy can depress blood counts, leading to anaemia with fatigue and dyspnoea, thrombocytopenia (bleeding), and/or neutropenia (infection). Blood counts need to be monitored until they recover. A history and physical examination should be performed every 4-6 months for the first 2 years and annually thereafter. Imaging of the chest (chest x-ray or computed tomography) should be performed on a similar schedule.[303]

For patients with metastatic disease who have completed palliative chemotherapy and/or radiotherapy, similar follow-up is recommended. The optimal follow-up schedule has not been defined.

Use of this content is subject to our disclaimer